Status:
UNKNOWN
Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Pneumonia
Coronavirus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Captopril being an effective drug available in liquid preparation, administration by nebulization could be of interest for maximizing lung action and minimizing systemic side effects. Such a treatment...
Detailed Description
Coronavirus Disease 2019 (COVID-19) is due to SARS-CoV-2 infection. The main cause of death is refractory acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 pneumonia. The SARS-CoV-2 m...
Eligibility Criteria
Inclusion
- Hospitalization for acute respiratory failure requiring oxygen administration ≥3L/mn
- Age \> 18 years or older
- Presence of pneumonia
- PCR SARS-CoV-2 positive in any biological sample in the last 7 days
- Patient affiliated to social security regime
- Written informed consent provided by the patient or alternatively by next-of-kin, or in emergency situations, prior to any protocol-specific procedures
Exclusion
- Decision of withholding invasive mechanical ventilation
- Shock requiring vasopressor infusion
- Co-infection with another respiratory pathogen which could be responsible of pneumonia
- Hypersensitivity to captopril, to any other angiotensin converting enzyme inhibitor or any of the excipients of the specialty used
- History of angio-oedema
- History of ACE-inhibitor allergy
- Known pregnancy or current lactation: Female subject of childbearing potential should have a negative serum pregnancy test prior to receiving the first dose of study medication.
- Patient who is currently enrolled in other investigational study;
- Persons deprived of their liberty by judicial or administrative decision,
- Persons under legal protection/safeguard of justice,
- Patients under duress psychiatric care,
- Persons admitted to a health or social institution
- Patient on state medical aid
Key Trial Info
Start Date :
May 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2020
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT04355429
Start Date
May 5 2020
End Date
August 1 2020
Last Update
April 28 2020
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Victor Dupuy- Argenteuil
Argenteuil, France
2
Hôpital Avicenne,
Bobigny, France, 93000
3
Hôpital Avicenne
Bobigny, France, 93000
4
Hôpital Avicenne
Bobigny, France